Share

    


In This Section

President's Theme 2020-2021

Randall-Oyer-200x200

Randall A. Oyer, MD, was named the Association of Community Cancer Centers (ACCC) President for 2020-2021 at the ACCC 46th Annual Meeting & Cancer Center Business Summit held March 4-6 in Washington, D.C.

ACCC invites each president to select a theme for their year in office that addresses a timely issue in cancer care through the creation of programs and resources. Dr. Oyer announced that the theme of his presidency will be “Community Oncology Can Close the Gap in Cancer Research.”

“Over the past year ACCC has heard from our members that there are gaps in community research,” said Dr. Oyer. Respondents to ACCC’s “2019 Trending Now in Cancer Care Survey” identified their top three challenges to offering patients with cancer clinical trials as staff resources and training (53%), program infrastructure (50%), and lack of patient understanding of the clinical trials process (46%). Citing these survey findings, Dr. Oyer remarked: “We have a serious imbalance in our clinical trials work. Our patients are in the community, yet the trials are at academic medical centers. And I believe that ACCC is uniquely situated to close this gap.”

Among the plans to achieve this goal outlined by Dr. Oyer were the following:

  • Creating a multidisciplinary taskforce to identify staff/program/patient education resources needed to accelerate implementation of clinical trials in ACCC member practices and programs
  • Bringing together experts at the 2020 ACCC Institute for the Future of Oncology forum to share best practices and learn more about challenges and barriers to clinical trials adoption
  • Developing a series of articles, blogs, and podcasts on effective practices in clinical trials accrual and management.

“We would like to improve our care and access for traditionally underserved communities. We would like to increase sensitivity, awareness, and understanding of the needs specific to geriatric oncology. And we would like to bring precision medicine into the community by understanding how to use the new precision diagnostics and radiology techniques to make sure that our patients have access to these services.”

The resources and tools that will be developed in conjunction with Dr. Oyer’s President’s Theme will be posted to this webpage as they are available.

Featured Program

ACCC Community Oncology Research Institute

The Association of Community Cancer Centers (ACCC) has established the ACCC Community Oncology Research Institute (ACORI) to build on its existing mission to close the gap in cancer research through optimal oncology partnerships.
Learn More

 

Featured Program


ASCO President Lori J. Pierce, MD, discusses the ASCO-ACCC Collaboration during her #ASCO21 President's Address.

ASCO-ACCC Initiative to Increase Racial and Ethnic Diversity in Clinical Trials

ACCC and ASCO are collaborating to increase cancer clinical trial participation among patients from underrepresented racial and ethnic groups. The two organizations are currently recruiting 40 oncology research programs to be part of a pilot program testing a site assessment tool and/or an implicit bias training program.
Learn More

 

From Oncology Issues

  •  Community Oncology Can Close the Gap in Cancer Research
    Amanda Patton, MA
    One of the ways in which community oncology is helping to close gaps in cancer research is through participation in the National Cancer Institute Community Oncology Research Program clinical trials. The Lahey Health Cancer Institute, a part of the Beth Israel Lahey Health System, continues to expand access to clinical trials and, in particular, the NCI National Clinical Trials Network into the community by partnering with affiliated community hospitals.
  •  Trending Now in Cancer Care
    Alexandria Howson, PhD
    Rather than fielding its annual Trending Now in Cancer Care survey while cancer programs were experiencing unprecedented challenges due to the extended public health emergency, ACCC chose to facilitate conversations with its members to capture the lived experiences of the most pertinent issues impacting oncology practice and care delivery.
  •  Community Oncology Can Close the Gap in Cancer Research
    Amanda Patton, MA
    This is the story of how a large independent practice in northwest Arkansas has nurtured its research program over several decades and is now able to offer patients access to phase I, II, and III trials close to home and their families.

ACCC & Inova Schar Cancer Institute Meet with Swedish Delegates

By Molly Kisiel, MSN, FNP-BC
March 14, 2024

On Tuesday, March 12, I had the privilege of joining Jennifer Bires, LCSW, OSW-C, CST, FACC, executive director of Life with Cancer and Patient Experience at Inova Schar Cancer Institute and newly elected member of the Board of Trustees for the Association of Cancer Care Centers (ACCC), at a meeting with delegates from the Swedish Ministry of Health and Social Affairs. During the meeting, which took place at Inova’s Life with Cancer clinic in Fairfax, Virginia, I provided an overview of ACCC's efforts to expand access to cancer care and alleviate the financial burdens on patients, highlighting recent advocacy initiatives on Capitol Hill. Bires shared the Cancer Institute's innovative approach to person-centered cancer care, with an emphasis on the invaluable psychosocial support offered by the Life with Cancer program.

One notable topic of discussion centered around the use of advanced practice providers (APPs) to expand the availability of healthcare providers—a practice integral to the multidisciplinary oncology care team in the United States. The absence of APPs in Sweden sparked interest among the delegates, with 1 expressing their admiration for the role of nurse practitioners based on prior experiences in the US and expressed a desire for similar expansion in Sweden.

Both the US and Sweden face challenges in cancer care access, albeit with different underlying causes. Sweden grapples with a shortage of oncologists as does the US, with the latter also confronting challenges rooted in social drivers of health, including financial barriers to the cost of treatment. The role of industry in promoting equitable and accessible care for all was acknowledged by all individuals present. 

A panel consisting of 4 members from Life with Cancer, including 2 nurse navigators, Laura Kaminski, BSN, RN, OCN, and Eva Ruiz Olivares, BSN, RN; an oncology behavioral therapist, Anna Harkins-Joseph, LCSW; and an oncology dietitian, Marion Irvin, RD, CSO, LD, CNSC, elaborated on their pivotal roles in providing continuous support to patients and their families from diagnosis to survivorship. Robust discussions ensued between the Swedish delegates and Inova staff regarding potential research opportunities focusing on the impact of psychosocial care on patient outcomes.

Stephanie Van Bebber, senior director of the Inova Schar Clinical Trials Office within the Inova Health System, provided an insightful overview of the ongoing research endeavors at the program—highlighting the expanding reach of trials into the Northern Virginia community. Van Bebber mentioned the enrollment rate of patients into cancer clinical trials at the cancer program currently stands at between 1% to 5%, but with a concerted effort to raise this figure over the next 3 years. Swedish delegates expressed a desire for all patients with cancer to be enrolled in trials, emphasizing the importance of maximizing participation rates. This aspiration aligns with several initiatives spearheaded by ACCC, such as the Just ASK training program in partnership with the American Society of Clinical Oncology (ASCO), aimed at enhancing clinical trial awareness and diversifying participation. Additionally, the ACCC Community Oncology Research Institute (ACORI)—launched under the tenure of past ACCC president, Randall A. Oyer, MD, FACC, executive medical director, Penn Medicine Lancaster General Health, Ann B. Barshinger Cancer Institute—endeavors to broaden access to clinical trials within community settings and reflects ACCC's commitment to advancing research and improving patient outcomes.

Kathleen Harnden, MD, MBA, director of Breast Medical Oncology at Inova Health System, provided valuable insights into the integration of cancer clinical trials within her program. Notably, she highlighted Inova's significant contribution as one of the leading enrollers in an ongoing clinical trial investigating a promising new approach to hormone therapy for patients with breast cancer. Dr. Harnden emphasized the importance of clinical trials in advancing treatment options and improving outcomes for patients. Further, she discussed how participation in such trials not only offers patients access to cutting-edge therapies but also contributes to the advancement of medical knowledge and the development of more effective treatments.

Jennifer Bires led the Swedish delegation on a tour of Inova Schar Cancer Institute and provided insights into the patient-centric design of Inova Schar Cancer spaces. The delegation then visited the Inova Saville Cancer Screening and Prevention Clinic, where Elizabeth Hatcher, MSN, FNP-BC, outlined the clinic's services and ongoing trials. Finally, the group explored the Radiation department on a tour led by Ann Miner, senior director of Radiation Oncology at Inova Health System, observing cutting-edge technologies, such as a proton beam, and facilities designed to cater to the needs of pediatric and adolescent patients.

As the meeting concluded, members of the Swedish delegation expressed their admiration for witnessing "words put into actions" during their visit. They conveyed their anticipation of bringing back valuable insights and learnings to their country, inspired by the innovative approaches and collaborative efforts witnessed today. This exchange of ideas and experiences serves as a testament to the importance of global cooperation in advancing cancer care and research, which will ultimately benefit patients worldwide.

The Swedish Delegation included members from the Ministry of Health and Social Affairs, Swecare Foundation, A3P Biomedical, AstraZeneca, Elypta, Karolinska Universitetssjukhuset, Micropos Medical, Nollvision Cancer, The Swedish Network against Cancer, Scibase, and Sprint BioScience.

Molly Kisiel, MSN, FNP-BC is director, Clinical Content, Editorial Content and Strategy, Association of Cancer Care Centers, Rockville, Maryland. Prior to this position, she spent 14 years working as a registered nurse, oncology nurse navigator, and nurse practitioner at the Inova Health System. 

More From ACCC

Clinical Trial Resources

  • Virtual Navigation to Clinical Trials
    Jan 4, 2019

    In the current oncology clinical trials landscape, many barriers remain to clinical trial enrollment that affect both the oncologist and the patient. Among these are trial locations, strict eligibility requirements, insufficient resources to support appropriate clinical trial education and screening, as well as patient and provider attitudes about trials.

  • IO Trials Are Accruing: Where Are the Patients?
    Sep 10, 2018

    Research nurse Joannne Riemer, RN, BSN,  started her position at Johns Hopkins Medical Institution in 2010. Within six months, she was working with checkpoint inhibitors. From her vantage point in clinical trials research, she discusses the many changes in IO clinical trials patient selection over the last eight years. 

Podcast

COVID-19 Resources

HHS-60x60combatCOVID.hhs.gov provides important information and links to access the most current treatment guidelines and inpatient and outpatient clinical trials.

Live and On-Demand Webinars